Tracking the LEGN option chain helps you see every strike and expiry on Legend Biotech Corp ADR in one view, so you can quickly identify the contracts that fit your thesis and your risk. Legend Biotech Corp ADR's option chain lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of LEGN options activity at a glance. Use our scanner to monitor the LEGN option chain in real time and filter for the LEGN options trades that actually meet your criteria.
An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For LEGN stock options, the chain shows side-by-side call and put data, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading the LEGN option chain effectively means looking beyond the last price — implied volatility by strike, volume-to-open-interest ratios, and bid-ask spreads all tell you where LEGN stock options are being actively traded and where they are not.
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma.
In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-hodgkins lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.
Credit spreads, long calls, iron condors, calendar trades — every strategy starts with the same raw material: a clean, complete option chain. Our scanner pulls Legend Biotech Corp ADR's full chain across every expiry, highlights the most liquid strikes, and lets you screen LEGN options by the metrics that matter, from IV skew to volume surges. Stop scrolling through endless rows of LEGN stock options — let the full option chain come to you, pre-filtered and ready to trade.
